Biodexa Pharmaceuticals PLC Banner Image

Biodexa Pharmaceuticals PLC

  • Ticker BDRX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Biodexa Pharmaceuticals PLC Logo Image
  • 11-50 Employees
  • Based in Cardiff, Wales
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma and diffuse midline glioma. MTX110 is a solubilised formulationMore of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and avoiding systemic toxicity.
4.8 / 5.0 (98)

Biodexa Pharmaceuticals PLC reports have an aggregate usefulness score of 4.8 based on 98 reviews.

Biodexa Pharmaceuticals PLC

Most Recent Annual Report

Biodexa Pharmaceuticals PLC
MOST RECENT 2023 Annual Report

Biodexa Pharmaceuticals PLC does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports

Biodexa Pharmaceuticals PLC Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!